ERFURT and
- AMP Roundtable Series Website: amp-eu.de/roundtable
AMP Roundtable Series: Episode #1, "Medical Cannabis in
The first episode in the Roundtable Series, "Medical Cannabis in
In the hour-long roundtable episode, Dr. Franjo Grotenhermen, a practicing German doctor and advisor to the German government regarding medical cannabis, joins Dr.
Mr.
Topics:
- Definition of cannabis and its history as a medicine,
- The current situation of medical cannabis in
Germany , - Which medical conditions may have benefited from cannabis?
- What clinical research is required to determine if cannabis has an effect?
- What medical conditions are covered by the German government insurance system, and what are the obstacles for patients to be reimbursed?
- What is the doctor and pharmacist's reaction to the introduction of medical cannabis as a medicine?
- What are the political and medical factors influencing access to patients?
- What are the supply and demand issues affecting patients?
- Outlook for medical cannabis demand in the coming years.
Panel Members:
Dr. Franjo Grotenhermen (MD)
Born in 1957, Dr. Grotenhermen studied medicine in
Dr. Grotenhermen is the executive director of the
Dr. Grotenhermen works at the nova-Institute in
For more information about IACM, please visit: www.cannabis-med.org
Dr.
Dr.
Mr.
Mr.
For more information, please visit www.holger-scholze.de
About Roundtable Sponsor,
CC Pharma is a leading importer and distributor of EU-pharmaceuticals for the German market. Founded in 1999, it has over 230 employees and offices in Germany, Denmark, Poland and the Czech Republic. CC Pharma holds 318 active German national pharmaceutical licenses and 692 active EU pharmaceutical licenses and operates a production, repackaging and labeling facility at its headquarters in Densborn, Germany. During 2018, CC Pharma generated revenue of approximately €262 million, with EBITDA of approximately €10.5 million.
For more information, please visit: www.cc-pharma.de
About
AMP has entered into a non-exclusive distribution agreement for medical cannabis with a leading distributor of pharmaceuticals products to more than 13,000 pharmacies throughout
For more information, please visit: www.amp-eu.com
AMP social media links:
- Twitter: https://twitter.com/AMP_Cannabis
- LinkedIn: www.linkedin.com/company/ampgermancannabisgroup
- Facebook: www.facebook.com/AMPGCG/
Media Kit: www.amp-eu.com/media-kit
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements that are based on the Company's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
SOURCE
© Canada Newswire, source